查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1896253

个人化医疗和基因组学市场预测至2032年：按产品、技术、应用、最终用户和地区分類的全球分析

Personalized Medicine & Genomics Market Forecasts to 2032 - Global Analysis By Product (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics and Medical Care), Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球个人化医疗和基因组学市场预计到 2025 年将达到 5,993.5 亿美元，到 2032 年将达到 10,609.4 亿美元，预测期内复合年增长率为 8.5%。

精准医疗是一种创新方法，它根据个人的基因组成、生活方式和环境量身定制医疗保健方案；而基因组学则专注于研究整个基因组，以了解影响健康和疾病的基因突变。结合这两种方法，我们可以识别影响药物反应、疾病风险和治疗结果的基因差异，从而实现精准的预防、诊断和治疗。与传统的「一刀切」式医疗不同，精准医疗利用基因组学资讯来选择最佳的治疗方案和剂量，从而提高疗效并减少副作用。基因组学技术的进步，例如全基因测序，使这一切成为可能，并将医疗保健转变为更具预测性、预防性和以患者为中心的实践。

对个人化治疗的需求日益增长

个人化医疗和基因组学市场的主要驱动力是对客製化疗法日益增长的需求。医疗保健正稳步从「一刀切」的治疗模式转向精准医疗，患者和临床医生越来越倾向于寻求根据其基因谱、疾病亚型和个别药物反应量身定制的治疗方法。这种转变将提高治疗效果，最大限度地减少不良反应，并改善患者预后。人们对基因检测的日益关注，以及定序技术的进步，正持续推动个人化医疗从小众方法走向主流临床实践。

个人化解决方案高成本

个人化医疗和基因组学的高成本仍然是限制市场成长的一大阻碍因素。先进的基因测序、生物资讯基础设施、伴随诊断和客製化治疗都需要大量的资金投入。这些费用限制了其可近性，尤其是在发展中地区和对成本较为敏感的医疗体系中。此外，报销难题和保险覆盖范围的不均衡也进一步阻碍了其普及。儘管技术成本正在逐步下降，但经济负担仍然是阻碍个人化医疗解决方案广泛应用的主要障碍。

巨量资料与人工智慧的融合

巨量资料分析与人工智慧的融合为个人化医疗和基因组学市场带来了巨大的成长机会。人工智慧驱动的工具能够快速分析海量基因组资料集，进而改善疾病预测、药物研发和治疗方法优化。巨量资料平台有助于发现传统分析方法无法检测到的潜在遗传模式和关联。随着医疗保健系统日益采用数位化基础设施，人工智慧驱动的基因组学有望加速临床决策，并实现可扩展的、数据驱动的个人化医疗。

资料安全和隐私风险

鑑于基因组数据的高度敏感性及其对个人隐私的深远影响，资料安全和隐私风险对个人化医疗和基因组学市场构成严重威胁。资料外洩、滥用和未授权存取可能会损害患者信任，并招致监管机构的审查。严格的资料保护法律和合规要求增加了市场相关人员的营运复杂性。如果缺乏强大的网路安全保障和合乎伦理的资料管治，保密性问题可能会减缓基因组技术的普及应用，并限制基因组创新所必需的大规模资料共用。

新冠疫情的影响：

新冠疫情对市场产生了复杂的影响，但最终加速了市场发展。基因测序在追踪病毒变异、疫苗研发以及了解个别患者对感染的反应方面发挥了关键作用。这场危机凸显了精准医疗在复杂疾病管理中的价值，并加速了对基因组学、生物资讯学和数位医疗基础设施的投资。然而，临床试验和常规诊断的短期中断暂时减缓了市场成长动能。

预计在预测期内，生物资讯学将占据最大的市场规模。

由于生物资讯学在管理、分析和解读复杂基因组数据方面发挥核心作用，预计在预测期内，生物资讯学领域将占据最大的市场份额。随着定序量的不断增长，先进的生物资讯学平台对于将原始遗传资讯转化为可操作的临床见解至关重要。人工智慧驱动的分析、基于云端的数据储存和运算工具在研究实验室和医疗机构中的日益普及，持续推动市场需求，使生物资讯学成为个人化医疗的基础。

预计在预测期内，肿瘤治疗领域将达到最高的复合年增长率。

预计在预测期内，肿瘤学领域将实现最高成长率，这主要得益于基因组学在癌症诊断、预后和标靶治疗研发中日益广泛的应用。癌症的遗传复杂性决定了个人化治疗方案的必要性，而精准肿瘤学与基因组学技术高度契合。癌症发生率的上升、伴随诊断的普及以及基因疗法在临床上的应用日益广泛，都将推动肿瘤学领域的成长，使其成为成长最快的应用领域。

占比最大的地区：

由于医疗基础设施不断完善、基因组学研究倡议日益增多以及政府对精准医疗项目的支持力度加大，亚太地区预计将在预测期内占据最大的市场份额。大规模的患者群体、慢性病盛行率的上升以及基因检测可及性的提高正在推动精准医疗技术的普及。中国、日本和印度等国家正在大力投资基因组学、生物资讯学和个人化医疗，从而巩固其在该地区的市场主导地位。

年复合成长率最高的地区：

在预测期内，北美预计将呈现最高的复合年增长率，这主要得益于其强大的技术领先地位、高昂的医疗保健支出以及对个性化医疗解决方案的早期应用。领先的基因组学公司、先进的研究机构以及完善的法规结构正在加速创新和商业化。人工智慧、巨量资料分析和精准肿瘤学的日益普及，以及有利的报销政策，正持续推动全部区域市场的快速成长。

免费客製化服务：

购买此报告的客户可以选择以下免费自订选项之一：

  • 公司概况
    • 对其他市场公司（最多 3 家公司）进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户要求，对主要国家的市场规模和复合年增长率进行估算和预测（註：可行性需确认）。
  • 竞争基准化分析
    • 根据主要企业的产品系列、地理覆盖范围和策略联盟基准化分析

目录

第一章执行摘要

第二章 前言

  • 摘要
  • 相关利益者
  • 调查范围
  • 调查方法
  • 研究材料

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 应用分析
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的感染疾病

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球个人化医疗和基因组学市场（按产品划分）

  • 个性化医疗诊断
    • 基因检测
    • 即时检测
    • 基于生物标记的检测
    • 伴随诊断
  • 个人化医疗治疗方法
    • 标靶治疗
    • 数位健康与保健解决方案
    • 基于药物基因体学的药物
  • 医疗保健
    • 个人化营养
    • 预防医学计划

6. 全球个人化医疗和基因组学市场（按技术划分）

  • 基因组学
  • 生物资讯学
  • 蛋白质体学
  • 数位健康平台
  • 代谢体学
  • 表观遗传学

7. 全球个人化医疗和基因组学市场（按应用划分）

  • 肿瘤学
  • 感染疾病
  • 心臟病学
  • 自体免疫疾病
  • 神经病学
  • 免疫学
  • 其他用途

8. 全球个人化医疗和基因组学市场（按最终用户划分）

  • 医院和诊所
  • 製药和生物技术公司
  • 诊断检查室
  • 学术和研究机构
  • 其他最终用户

9. 全球个人化医疗和基因组学市场（按地区划分）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美国家
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章：重大进展

  • 协议、伙伴关係、合作和合资企业
  • 併购
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十一章 企业概况

  • Illumina, Inc.
  • Genomic Health, Inc.
  • Thermo Fisher Scientific, Inc.
  • Gilead Sciences, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthineers AG
  • Novartis AG
  • Foundation Medicine, Inc.
  • Pfizer Inc.
  • Guardant Health, Inc.
  • Bristol Myers Squibb
  • Bio-Rad Laboratories, Inc.
  • Merck &Co., Inc.
  • Agilent Technologies, Inc.
  • Qiagen NV
Product Code: SMRC32941

According to Stratistics MRC, the Global Personalized Medicine & Genomics Market is accounted for $599.35 billion in 2025 and is expected to reach $1,060.94 billion by 2032 growing at a CAGR of 8.5% during the forecast period. Personalized medicine is an innovative approach that tailors healthcare to an individual's genetic makeup, lifestyle, and environment, while genomics focuses on studying the entire genome to understand variations influencing health and disease. Together, they enable precise prevention, diagnosis, and treatment by identifying genetic differences that affect drug response, disease risk, and therapy outcomes. Unlike traditional "one-size-fits-all" medicine, personalized medicine uses genomic insights to select optimal treatments and dosages, improving effectiveness and reducing side effects. Genomics advances, such as whole genome sequencing, have made this possible, transforming medicine into a more predictive, preventive, and patient-centered practice.

Market Dynamics:

Driver:

Rising Demand for Tailored Therapies

The rising demand for tailored therapies is a primary driver of the personalized medicine and genomics market, as healthcare steadily moves away from blanket treatments toward precision-based care. Patients and clinicians increasingly seek therapies aligned with genetic profiles, disease subtypes, and individual drug responses. This shift improves treatment efficacy, minimizes adverse effects, and enhances patient outcomes. Growing awareness of genetic testing, coupled with advancements in sequencing technologies, continues to push personalized medicine from a niche approach into mainstream clinical practice.

Restraint:

High Costs of Personalized Solutions

High costs associated with personalized medicine and genomics remain a significant restraint on market growth. Advanced genomic sequencing, bioinformatics infrastructure, companion diagnostics, and customized therapies require substantial financial investment. These expenses limit accessibility, particularly in developing regions and cost-sensitive healthcare systems. Additionally, reimbursement challenges and uneven insurance coverage further slow adoption. While technology costs are gradually declining, the economic burden continues to hinder widespread implementation of personalized healthcare solutions.

Opportunity:

Integration of Big Data & AI

The integration of big data analytics and artificial intelligence presents a major growth opportunity for the personalized medicine and genomics market. AI-driven tools enable rapid analysis of vast genomic datasets, improving disease prediction, drug discovery, and treatment optimization. Big data platforms help uncover hidden genetic patterns and correlations that traditional analysis cannot detect. As healthcare systems increasingly adopt digital infrastructure, AI-powered genomics is set to accelerate clinical decision-making and unlock scalable, data-driven personalized care.

Threat:

Data Security and Privacy Risks

Data security and privacy risks pose a serious threat to the personalized medicine and genomics market, as genomic data is highly sensitive and deeply personal. Breaches, misuse, or unauthorized access can undermine patient trust and invite regulatory scrutiny. Strict data protection laws and compliance requirements increase operational complexity for market players. Without robust cybersecurity frameworks and ethical data governance, concerns over confidentiality may slow adoption and limit large-scale data sharing essential for genomic innovation.

Covid-19 Impact:

The COVID-19 pandemic had a mixed but ultimately accelerating impact on the market. Genomic sequencing played a critical role in tracking virus mutations, vaccine development, and understanding patient-specific responses to infection. The crisis highlighted the value of precision medicine in managing complex diseases and accelerated investments in genomics, bioinformatics, and digital health infrastructure. However, short-term disruptions in clinical trials and routine diagnostics temporarily slowed market momentum.

The bioinformatics segment is expected to be the largest during the forecast period

The bioinformatics segment is expected to account for the largest market share during the forecast period, due to its central role in managing, analyzing, and interpreting complex genomic data. As sequencing volumes increase, advanced bioinformatics platforms are essential for transforming raw genetic information into actionable clinical insights. Growing adoption of AI-driven analytics, cloud-based data storage, and computational tools across research and healthcare settings continues to fuel demand, making bioinformatics the backbone of personalized medicine.

The oncology segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the oncology segment is predicted to witness the highest growth rate, due to growing application of genomics in cancer diagnosis, prognosis, and targeted therapy development. Cancer's genetic complexity demands personalized treatment approaches, making precision oncology a natural fit for genomic technologies. Rising cancer prevalence, increasing use of companion diagnostics, and expanding clinical adoption of gene-based therapies are accelerating growth and positioning oncology as the fastest-growing application area.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to expanding healthcare infrastructure, rising genomic research initiatives, and increasing government support for precision medicine programs. Large patient populations, growing prevalence of chronic diseases, and improving access to genetic testing are driving adoption. Countries such as China, Japan, and India are investing heavily in genomics, bioinformatics, and personalized healthcare, strengthening the region's dominant market position.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to strong technological leadership, high healthcare spending, and early adoption of personalized medicine solutions. The presence of major genomics companies, advanced research institutions, and supportive regulatory frameworks accelerates innovation and commercialization. Increasing use of AI, big data analytics, and precision oncology, along with favorable reimbursement trends, continues to propel rapid market growth across the region.

Key players in the market

Some of the key players in Personalized Medicine & Genomics Market include Illumina, Inc., Genomic Health, Inc., Thermo Fisher Scientific, Inc., Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Novartis AG, Foundation Medicine, Inc., Pfizer Inc., Guardant Health, Inc., Bristol Myers Squibb, Bio-Rad Laboratories, Inc., Merck & Co., Inc., Agilent Technologies, Inc., and Qiagen N.V.

Key Developments:

In November 2025, Siemens Healthineers introduced Syngo Carbon 2.0, an upgraded enterprise imaging platform. The launch integrates multimodal imaging data, AI-powered workflow automation, and cloud-based collaboration, designed to streamline radiology operations and improve diagnostic accuracy across global healthcare systems.

In October 2025, Siemens Healthineers expanded its collaboration with Varian and multiple oncology centers to accelerate precision therapy solutions. The joint venture integrates imaging, radiation therapy, and AI-driven planning tools, aiming to improve cancer treatment outcomes and strengthen Siemens' leadership in oncology care.

Products Covered:

  • Personalized Medicine Diagnostics
  • Personalized Medicine Therapeutics
  • Medical Care

Technologies Covered:

  • Genomics
  • Bioinformatics
  • Proteomics
  • Digital Health Platforms
  • Metabolomics
  • Epigenetics

Applications Covered:

  • Oncology
  • Infectious Diseases
  • Cardiology
  • Autoimmune Diseases
  • Neurology
  • Immunology
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Personalized Medicine & Genomics Market, By Product

  • 5.1 Introduction
  • 5.2 Personalized Medicine Diagnostics
    • 5.2.1 Genetic Testing
    • 5.2.2 Point-of-Care Testing
    • 5.2.3 Biomarker-Based Tests
    • 5.2.4 Companion Diagnostics
  • 5.3 Personalized Medicine Therapeutics
    • 5.3.1 Targeted Therapies
    • 5.3.2 Digital Health & Wellness Solutions
    • 5.3.3 Pharmacogenomics-Based Drugs
  • 5.4 Medical Care
    • 5.4.1 Personalized Nutrition
    • 5.4.2 Preventive Care Programs

6 Global Personalized Medicine & Genomics Market, By Technology

  • 6.1 Introduction
  • 6.2 Genomics
  • 6.3 Bioinformatics
  • 6.4 Proteomics
  • 6.5 Digital Health Platforms
  • 6.6 Metabolomics
  • 6.7 Epigenetics

7 Global Personalized Medicine & Genomics Market, By Application

  • 7.1 Introduction
  • 7.2 Oncology
  • 7.3 Infectious Diseases
  • 7.4 Cardiology
  • 7.5 Autoimmune Diseases
  • 7.6 Neurology
  • 7.7 Immunology
  • 7.8 Other Applications

8 Global Personalized Medicine & Genomics Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Pharmaceutical & Biotechnology Companies
  • 8.4 Diagnostic Laboratories
  • 8.5 Academic & Research Institutes
  • 8.6 Other End Users

9 Global Personalized Medicine & Genomics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Illumina, Inc.
  • 11.2 Genomic Health, Inc.
  • 11.3 Thermo Fisher Scientific, Inc.
  • 11.4 Gilead Sciences, Inc.
  • 11.5 F. Hoffmann-La Roche Ltd.
  • 11.6 Siemens Healthineers AG
  • 11.7 Novartis AG
  • 11.8 Foundation Medicine, Inc.
  • 11.9 Pfizer Inc.
  • 11.10 Guardant Health, Inc.
  • 11.11 Bristol Myers Squibb
  • 11.12 Bio-Rad Laboratories, Inc.
  • 11.13 Merck & Co., Inc.
  • 11.14 Agilent Technologies, Inc.
  • 11.15 Qiagen N.V.

List of Tables

  • Table 1 Global Personalized Medicine & Genomics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Personalized Medicine & Genomics Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Personalized Medicine & Genomics Market Outlook, By Personalized Medicine Diagnostics (2024-2032) ($MN)
  • Table 4 Global Personalized Medicine & Genomics Market Outlook, By Genetic Testing (2024-2032) ($MN)
  • Table 5 Global Personalized Medicine & Genomics Market Outlook, By Point-of-Care Testing (2024-2032) ($MN)
  • Table 6 Global Personalized Medicine & Genomics Market Outlook, By Biomarker-Based Tests (2024-2032) ($MN)
  • Table 7 Global Personalized Medicine & Genomics Market Outlook, By Companion Diagnostics (2024-2032) ($MN)
  • Table 8 Global Personalized Medicine & Genomics Market Outlook, By Personalized Medicine Therapeutics (2024-2032) ($MN)
  • Table 9 Global Personalized Medicine & Genomics Market Outlook, By Targeted Therapies (2024-2032) ($MN)
  • Table 10 Global Personalized Medicine & Genomics Market Outlook, By Digital Health & Wellness Solutions (2024-2032) ($MN)
  • Table 11 Global Personalized Medicine & Genomics Market Outlook, By Pharmacogenomics-Based Drugs (2024-2032) ($MN)
  • Table 12 Global Personalized Medicine & Genomics Market Outlook, By Medical Care (2024-2032) ($MN)
  • Table 13 Global Personalized Medicine & Genomics Market Outlook, By Personalized Nutrition (2024-2032) ($MN)
  • Table 14 Global Personalized Medicine & Genomics Market Outlook, By Preventive Care Programs (2024-2032) ($MN)
  • Table 15 Global Personalized Medicine & Genomics Market Outlook, By Technology (2024-2032) ($MN)
  • Table 16 Global Personalized Medicine & Genomics Market Outlook, By Genomics (2024-2032) ($MN)
  • Table 17 Global Personalized Medicine & Genomics Market Outlook, By Bioinformatics (2024-2032) ($MN)
  • Table 18 Global Personalized Medicine & Genomics Market Outlook, By Proteomics (2024-2032) ($MN)
  • Table 19 Global Personalized Medicine & Genomics Market Outlook, By Digital Health Platforms (2024-2032) ($MN)
  • Table 20 Global Personalized Medicine & Genomics Market Outlook, By Metabolomics (2024-2032) ($MN)
  • Table 21 Global Personalized Medicine & Genomics Market Outlook, By Epigenetics (2024-2032) ($MN)
  • Table 22 Global Personalized Medicine & Genomics Market Outlook, By Application (2024-2032) ($MN)
  • Table 23 Global Personalized Medicine & Genomics Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 24 Global Personalized Medicine & Genomics Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 25 Global Personalized Medicine & Genomics Market Outlook, By Cardiology (2024-2032) ($MN)
  • Table 26 Global Personalized Medicine & Genomics Market Outlook, By Autoimmune Diseases (2024-2032) ($MN)
  • Table 27 Global Personalized Medicine & Genomics Market Outlook, By Neurology (2024-2032) ($MN)
  • Table 28 Global Personalized Medicine & Genomics Market Outlook, By Immunology (2024-2032) ($MN)
  • Table 29 Global Personalized Medicine & Genomics Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 30 Global Personalized Medicine & Genomics Market Outlook, By End User (2024-2032) ($MN)
  • Table 31 Global Personalized Medicine & Genomics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 32 Global Personalized Medicine & Genomics Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 33 Global Personalized Medicine & Genomics Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 34 Global Personalized Medicine & Genomics Market Outlook, By Academic & Research Institutes (2024-2032) ($MN)
  • Table 35 Global Personalized Medicine & Genomics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.